(CIDRAP News) The Food and Drug Administration (FDA) has completed a new inspection of BioPort Corp., the only US manufacturer of the anthrax vaccine, and a company official is predicting approval of the facility after a few remaining concerns are ironed out.
Dec 4, 2003 (CIDRAP News) Thousands of US Customs and Border Protection (CBP) officers will help the Food and Drug Administration (FDA) inspect imported food under an agreement signed yesterday, according to the FDA.
(CIDRAP News) Because of a small theoretical risk that anthrax spores can hide in the lungs for up to 100 days and grow after antibiotic treatment is stopped, the anthrax vaccine and an extension of antibiotic treatment will be offered to people who may have been exposed in the recent anthrax attacks, federal health officials announced yesterday afternoon.
(CIDRAP News) The US House of Representatives on Wednesday overwhelmingly approved a bill authorizing about $2.9 billion in spending on preparedness for bioterrorism and other public health emergencies.
(CIDRAP News) Rapid tests for detecting anthrax spores on surfaces should not be used alone as the basis for public health or clinical decisions, the Centers for Disease Control and Prevention warned in today's issue of Morbidity and Mortality Weekly Report.
(CIDRAP News) A new study commissioned by the US Department of Agriculture (USDA) indicates that the risk of bovine spongiform encephalopathy (BSE) occurring in the United States is extremely low, but USDA officials who released the study said they are considering taking steps to lower the risk further.
Nov 29, 2001 (CIDRAP News) The US Department of Health and Human Services (HHS) has awarded Acambis Inc. a $428 million contract to produce an additional 155 million doses of smallpox vaccine by the end of 2002, HHS Secretary Tommy G. Thompson announced Wednesday.
(CIDRAP News) The Food and Drug Administration (FDA) published a notice in the Federal Register this week to make clear that doxycycline and penicillin G procaine, along with ciprofloxacin, already are approved for use as postexposure prophylaxis following inhalational exposure to anthrax. The notice also details postexposure dosing regimens for these medications.